Integrated Filing — IndAS



General information about company

Scrip Code 544619
NSE Symbol SUDEEPPHRM
MSEI Symbol NOTLISTED
ISIN INE0QPI01025
Name of company SUDEEP PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 28-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 28-10-2026   15:10:00
End date and time of board meeting 28-10-2026   16:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 19,669.91 35,496.96
Other income 598.43 1,142.97
Total income 20,268.34 36,639.93
2 Expenses
(a) Cost of materials consumed 7,137.04 14,017.61
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (185.63) (1,407.12)
(d) Employee benefit expense 1,561.03 2,995.00
(e) Finance costs 281.31 487.64
(f) Depreciation, depletion and amortisation expense 537.61 937.69
(f) Other Expenses
1 Other Expenses 3,833.73 7,076.60
Total other expenses 3,833.73 7,076.60
Total expenses 13,165.09 24,107.42
3 Total profit before exceptional items and tax 7,103.25 12,532.51
4 Exceptional items 0.00 0.00
5 Total profit before tax 7,103.25 12,532.51
6 Tax expense
7 Current tax 1,821.77 3,049.44
8 Deferred tax 100.37 243.27
9 Total tax expenses 1,922.14 3,292.71
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 5,181.11 9,239.80
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 5,181.11 9,239.80
17 Other comprehensive income net of taxes (22.23) (27.44)
18 Total Comprehensive Income for the period 5,158.88 9,212.36
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 5,145.24 9,200.24
Total comprehensive income for the period attributable to owners of parent non-controlling interests 35.87 39.56
21 Details of equity share capital
Paid-up equity share capital 0.00 0.00
Face value of equity share capital 0 0
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.59 8.18
Diluted earnings (loss) per share from continuing operations 4.59 8.18
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.59 8.18
Diluted earnings (loss) per share from continuing and discontinued operations 4.59 8.18
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 40,056.54
Capital work-in-progress 5,378.15
Investment property 4,389.34
Goodwill 6,745.00
Other intangible assets 13.95
Intangible assets under development 1,179.79
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current
Loans, non-current 0.00
Other non-current financial assets
1 Other non-current financial assets 468.78
Total of other non-current financial assets 468.78
Total non-current financial assets 468.78
Deferred tax assets (net) 113.30
Other non-current assets
1 Other non-current assets 2,185.19
Total of other non-current assets 2,185.19
Total non-current assets 60,530.04
2 Current assets
Inventories 27,494.99
Current financial asset
Current investments 0.00
Trade receivables, current 24,609.21
Cash and cash equivalents 5,379.00
Bank balance other than cash and cash equivalents 6,134.01
Loans, current 539.39
Other current financial assets
Total of other current financial assets 8,176.06
Total current financial assets 44,837.67
Current tax assets (net)
Other current assets
Total of other current assets
Total current assets 72,332.66
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,32,862.70
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,129.49
Other equity 94,602.34
Total equity attributable to owners of parent 95,731.83
Non controlling interest 1,551.10
Total equity 97,282.93
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 6,242.68
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Other non-current financial liabilities 3,146.87
Total of other non-current financial liabilities 3,146.87
Total non-current financial liabilities 9,389.55
Provisions, non-current 58.17
Deferred tax liabilities (net) 1,243.77
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 10,691.49
Current liabilities
Current financial liabilities
Borrowings, current 12,524.78
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 444.47
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 9,318.18
Total Trade payable 9,762.65
Other current financial liabilities
1 Other current financial liabilities 1,402.26
Total of other current financial liabilities 1,402.26
Total current financial liabilities 23,689.69
Other current liabilities 563.18
1 Other current liabilities 479.44
2 Lease liabilities 83.74
Total of other current liabilities 563.18
Provisions, current 92.03
Current tax liabilities (Net) 543.38
Deferred government grants, Current
Total current liabilities 24,888.28
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 35,579.77
Total equity and liabilites 1,32,862.70
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceutical, food and nutrition 14,249.96 25,091.33
2 Speciality ingredients 5,419.95 10,405.63
3 Inter-segment revenues 0.0031541 0.005245
Total Segment Revenue 19,985.32 36,021.46
Less: Inter segment revenue 315.41 524.50
Revenue from operations 19,669.91 35,496.96
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceutical, food and nutrition 5,512.34 9,514.79
2 Speciality ingredients 1,273.79 2,362.39
3 Inter-segment revenues 0.00 0.00
Total Profit before tax 6,786.13 11,877.18
i. Finance cost 281.31 487.64
ii. Other Unallocable Expenditure net off Unallocable income (598.43) (1,142.97)
Profit before tax 7,103.25 12,532.51
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceutical, food and nutrition 85,230.56 85,230.56
2 Speciality ingredients 47,518.85 47,518.85
3 Inter-segment revenues 0.00 0.00
Total Segment Asset 1,32,749.41 1,32,749.41
Un-allocable Assets 113.29 113.29
Net Segment Asset 1,32,862.70 1,32,862.70
4 Segment Liabilities
Segment Liabilities
1 Pharmaceutical, food and nutrition 24,488.74 24,488.74
2 Speciality ingredients 9,303.88 9,303.88
3 Inter-segment revenues 0.00 0.00
Total Segment Liabilities 33,792.62 33,792.62
Un-allocable Liabilities 1,787.15 1,787.15
Net Segment Liabilities 35,579.77 35,579.77
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 20.51 11.95
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 1.72 15.49
5 Total Other comprehensive income (22.23) (27.44)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 12,532.51
Adjustments for reconcile profit (loss)
Adjustments for finance costs 487.64
Adjustments for decrease (increase) in inventories (5,890.34)
Adjustments for decrease (increase) in trade receivables, current (1,540.97)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (2,161.18)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (22.78)
Adjustments for other financial assets, current 17.67
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,271.60
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (375.24)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 937.69
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (29.68)
Adjustments for provisions, non-current 38.87
Adjustments for other financial liabilities, current 339.06
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (627.09)
Adjustments for dividend income 0.00
Adjustments for interest income 290.12
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (10.02)
Other adjustments for non-cash items (66.06)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (5,920.95)
Net cash flows from (used in) operations 6,611.56
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,261.25
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,350.31
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment (19.31)
Proceeds from sales of investment property (7,753.62)
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 290.12
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 4,158.63
Net cash flows from (used in) investing activities (3,285.56)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 4,505.24
Repayments of borrowings 592.26
Payments of lease liabilities 45.54
Dividends paid 1,694.04
Interest paid 561.02
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 1,612.38
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 2,677.13
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 27.95
Net increase (decrease) in cash and cash equivalents 2,705.08
Cash and cash equivalents cash flow statement at beginning of period 2,673.92
Cash and cash equivalents cash flow statement at end of period 5,379.00